What is Sunset Neurological Group?
Sunset Neurological Group operates as a premier healthcare provider headquartered in Miami, focusing on comprehensive psychiatric and neurological care for patients aged 14 and older. The organization distinguishes itself through a multidisciplinary approach to mental health, offering specialized evaluations and evidence-based treatment plans for conditions such as ADHD, anxiety, and major depressive disorder. A core component of their clinical strategy involves the integration of advanced therapeutic technologies, including NeuroStar TMS, which provides a critical alternative for patients who have not achieved success with traditional pharmacological interventions. By prioritizing personalized recovery pathways and maintaining broad insurance accessibility, the group has established a sustainable model for high-acuity mental health service delivery.
How much funding has Sunset Neurological Group raised?
Sunset Neurological Group has raised a total of $1M across 2 funding rounds:
Debt
$500K
Debt
$500K
Debt (2024): $500K, investors not publicly disclosed
Debt (2024): $500K, investors not publicly disclosed
Key Investors in Sunset Neurological Group
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Sunset Neurological Group?
With the successful closure of this major strategic investment, Sunset Neurological Group is poised to accelerate its growth trajectory through the expansion of its clinical facilities and the potential integration of additional diagnostic technologies. The firm's focus on scaling its neurological service offerings suggests a strategic intent to capture a larger share of the regional market while maintaining the high standards of care that define its current operations. Future initiatives will likely center on optimizing patient throughput and enhancing the efficacy of its TMS-based treatment programs. As the organization matures, the focus will shift toward long-term operational sustainability and the potential for broader geographic reach, ensuring that its specialized psychiatric services remain accessible to a growing patient demographic in need of advanced neurological support.
See full Sunset Neurological Group company page
